Nuvalent Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
71.64
1.67
(2.39%)
Volume:
677,087
52 week range:
55.54 - 113.51
Market Cap:
5.129B
Company Description:
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations.